# Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

> **NCT03815474** · PHASE2 · UNKNOWN · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 47 (estimated)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** anlotinib

## Key facts

- **NCT ID:** NCT03815474
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-20
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2019-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815474, "Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03815474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*